Overview
This is a prospective non-randomized clinical trial to evaluate the feasibility of 3 fraction versus a standard 4 fraction high dose rate brachytherapy regimen in patients with locally advanced cervical cancer.
Eligibility
Inclusion Criteria:
- Histologically documented malignancy of the cervix and planned to receive brachytherapy as part of definitive treatment.
- ECOG performance status of 0-2
- Age ≥ 18 years old.
- Ability to understand and the willingness to provide written informed consent.
Exclusion Criteria:
- Contraindication to receiving radiotherapy as determined by treating radiation oncologist.
- Contraindication to receiving MRI.
- Prior radiation to the pelvis > 3 months ago
- Age < 18 years old.
- Pregnant or breast-feeding